Even given recent advances in nanomedicine development of breast cancer treatment in
recent years and promising results in pre-clinical models, cancer nanomedicines often fail at …

Doxorubicin is a widely used and promising anticancer drug; however, a severe dose-
dependent cardiotoxicity hampers its therapeutic value. Doxorubicin may cause acute and …

Doxorubicin (DOX), as a kind of chemotherapy agent with remarkable therapeutic effect, can
be used to treat diverse malignant tumors clinically. Dose-dependent cardiotoxicity is the …

Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …

Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating
research to improve diagnostics, and to discover and test novel preventive and curative …

Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of
anthracycline therapy. Identification of genes and genetic variants associated with AIC risk …

Innate immune cells are the early responders to infection and tissue damage. They play a
critical role in the initiation and resolution of inflammation in response to insult as well as …

Objectives There are presently a few viable ways to reduce cardiotoxicity of doxorubicin
(Dox). The combination of chemotherapy agents with natural compounds delivers greater …

As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time-and
dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription …

Chemotherapeutic treatment with conventional drug formulations pose numerous
challenges, such as poor solubility, high cytotoxicity and serious off‐target side effects, low …